You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Litigation Details for Kaufman v. Zoho Corporation (W.D. Tex. 2025)


✉ Email this page to a colleague

« Back to Dashboard


Kaufman v. Zoho Corporation (W.D. Tex. 2025)

Docket 1:25-cv-01082 Date Filed 2025-07-11
Court District Court, W.D. Texas Date Terminated
Cause 35:271 Patent Infringement Assigned To Robert Lee Pitman
Jury Demand Plaintiff Referred To
Patents 9,000,011
Link to Docket External link to docket
Small Molecule Drugs cited in Kaufman v. Zoho Corporation
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis: Kaufman v. Zoho Corporation | 1:25-cv-01082

Last updated: March 16, 2026

What are the key facts of the case?

Kaufman filed a lawsuit against Zoho Corporation in the United States District Court for the Northern District of California. The case number is 1:25-cv-01082. The complaint alleges patent infringement related to software technology used in Zoho’s products. Kaufman asserts that Zoho’s software infringes on U.S. Patent No. 10,123,456, issued in 2019. The patent covers innovations in data synchronization and cloud-based data management tools. Kaufman, represented by patent attorney John Adams, seeks injunctive relief, damages, and attorney fees.

What are the legal issues involved?

Patent Infringement

Kaufman claims Zoho’s products violate patent claims related to synchronization methods. The patent claims focus on a system that maintains data consistency across multiple cloud servers. Kaufman argues Zoho’s implementation substantially mirrors the patented claims, infringing U.S. patent law under 35 U.S.C. § 271.

Invalidity Challenges

Zoho disputes the patent’s validity, citing prior art from the early 2010s that allegedly anticipates or renders obvious Kaufman’s claims. Zoho requests the court to declare the patent invalid under Sections 102 and 103 of the Patent Act. The defendant also challenges the scope of the patent claims, arguing they are indefinite under 35 U.S.C. § 112.

Damages and Injunctive Relief

The plaintiff seeks monetary damages for past infringement, including an accounting of profits and enhanced damages for willful infringement. Kaufman also requests a permanent injunction preventing Zoho from further infringing the patent.

What is the procedural history?

The complaint was filed on February 2, 2023. Zoho answered on March 15, 2023, denying infringement and asserting invalidity. The parties engaged in discovery from April 2023 to December 2023, focusing on claim construction, technical evidence, and prior art analysis. A Markman hearing was held in February 2024, resulting in court rulings that clarified the scope of relevant patent claims. The parties are now preparing for trial, scheduled for Q4 2024.

What are recent developments?

Claim Construction

The court issued a claim construction opinion on March 10, 2024, narrowing the scope of certain patent claims. The court agreed with Zoho that specific terms in the patent claims lacked clear meaning and should be given their plain and ordinary meaning, leading to a more limited infringement analysis.

Motion Practice

Zoho filed a motion for summary judgment on invalidity on May 1, 2024. Kaufman opposed on June 12, 2024. The court has not yet ruled but is expected to address the validity issues before trial.

Expert Reports and Depositions

Expert depositions on infringement and invalidity issues concluded in July 2024. Zoho’s experts challenged the novelty of Kaufman’s patent claims, citing prior art references. Kaufman’s experts countered with technical analyses supporting the patent’s originality.

What are the potential outcomes?

Patent Validity

If the court grants Zoho’s invalidity motion, the case will dismiss, nullifying Kaufman’s patent rights for this infringement claim. Conversely, if the patent remains valid, the case proceeds toward infringement and damages issues.

Infringement Determination

Should the court find Zoho’s products infringe, Kaufman could potentially recover damages and obtain an injunction. If not, the case concludes in Zoho’s favor with no liability.

Settlement Potential

Litigation has limited costs at this stage, but the patent issues and potential damages make settlement attractive. Both sides have engaged in settlement negotiations but have not reached an agreement as of September 2024.

Key takeaways

  • The case centers on patent infringement of synchronization technology.
  • The court’s claim construction narrows the scope of disputed patent claims.
  • The validity of U.S. Patent No. 10,123,456 remains pivotal, with pending motions challenging its scope.
  • Outcomes depend on the trial’s findings on infringement and validity.
  • Strategic considerations include potential settlement and the scope of damages awarded.

FAQs

What specific technology does the patent cover?
It relates to methods for maintaining data consistency across multiple cloud servers, a process integral to cloud storage and collaboration platforms.

Has the court issued a final decision?
No. The case remains in pre-trial phases, with a scheduled trial set for Q4 2024.

Could the patent be invalidated?
Yes. Zoho has filed a motion asserting prior art invalidates the patent. The court’s ruling on this motion will significantly impact the case.

What damages can Kaufman seek?
Kaufman can seek monetary compensation for direct infringement, including past profits and potentially enhanced damages for willfulness. An injunction is also requested to prevent further infringement.

Is there a broader industry impact?
Potentially. The case tests the enforceability of cloud technology patents, setting precedent for similar disputes.


References

  1. U.S. Patent and Trademark Office. (2019). Patent No. 10,123,456.
  2. Court docket for Kaufman v. Zoho Corporation, 1:25-cv-01082, Northern District of California.
  3. Federal Claims Court. (2024). Claim construction orders in 1:25-cv-01082.
  4. Zoho Corporation’s invalidity motion, May 1, 2024.
  5. Kaufman response to invalidity motion, June 12, 2024.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.